» Articles » PMID: 28797188

Validation of Psychometric Properties and Development of Response Criteria for the Psoriasis Symptoms and Signs Diary (PSSD): Results from a Phase 3 Clinical Trial

Overview
Publisher Informa Healthcare
Specialty Dermatology
Date 2017 Aug 12
PMID 28797188
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The Psoriasis Symptoms and Signs Diary (PSSD) is a patient-reported instrument that assesses severity of six symptoms (itch, skin tightness, burning, stinging, and pain) and five signs (dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of psoriasis.

Materials And Methods: PSSD symptoms and signs summary scores (range, 0-100) were derived based on individual item scores (0-10 [absent-worst imaginable]). Using Psoriasis Area and Severity Index [PASI], Investigator's Global Assessment [IGA] and Dermatology Life Quality Index [DLQI]) data from the NAVIGATE trial of patients with moderate-to-severe psoriasis, analyses were conducted to further validate the PSSD (7-day recall version) and establish criteria for clinically meaningful improvements (CMIs).

Results: Mean PSSD symptoms and signs summary scores were 50.6 and 60.7, respectively, at baseline, with no major floor (score of 0) or ceiling (maximum score) effects. PSSD scores and changes in PSSD scores were highly correlated with PASI, IGA, and DLQI scores (most Spearman's correlation r's ≥0.4, all p < .001). A 2-grade improvement in IGA or an improvement of 75%-<90% in PASI was associated with CMIs of ≥40-points in PSSD summary scores and ≥3-5-points in individual item scores.

Conclusions: The PSSD possesses strong psychometric properties and is suitable for use as a measure of disease severity in clinical studies of patients with moderate-to-severe psoriasis.

Citing Articles

TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis.

Mercadal-Orfila G, Lopez Sanchez P, Pou Alonso A, Ibarra-Barrueta O, Monte-Boquet E, Borras Blasco J Front Med (Lausanne). 2024; 11:1465725.

PMID: 39720651 PMC: 11667264. DOI: 10.3389/fmed.2024.1465725.


Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study.

Tada Y, Armstrong A, Imafuku S, Okubo Y, Morita A, Zhong Y J Dermatol. 2024; 52(2):353-358.

PMID: 39641509 PMC: 11807358. DOI: 10.1111/1346-8138.17570.


Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial.

Errichetti E, Wolf P, Khattri S, Gorecki P, Miller M, Jiang J Acta Derm Venereol. 2024; 104:adv41053.

PMID: 39233617 PMC: 11388105. DOI: 10.2340/actadv.v104.41053.


Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.

Armstrong A, Augustin M, Beaumont J, Pham T, Hudgens S, Gordon K Dermatol Ther (Heidelb). 2024; 14(8):2235-2248.

PMID: 39080153 PMC: 11333388. DOI: 10.1007/s13555-024-01224-x.


Study of the Involvement of the P2Y12 Receptor in Chronic Itching in Type 2 Diabetes Mellitus.

Xu X, Zhang H, Li L, Yang R, Li G, Liu S Mol Neurobiol. 2022; 59(3):1604-1618.

PMID: 35000152 DOI: 10.1007/s12035-021-02676-4.